The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): A multi-institute phase II study in resectable metastases.
Robert Peter Jones
Honoraria - Biocompatibles
Research Funding - Biocompatibles
Hassan Zakria Malik
No relevant relationships to disclose
Stephen W Fenwick
Honoraria - Biocompatibles
Clare Byrne
No relevant relationships to disclose
Monica Terlizzo
No relevant relationships to disclose
Elizabeth O'Grady
No relevant relationships to disclose
Stefan Stremitzer
No relevant relationships to disclose
Thomas Gruenberger
Consultant or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Honoraria - Amgen; Bayer; Merck Serono; Roche
Research Funding - Amgen; Bayer; Merck Serono; Roche
Graeme John Poston
Consultant or Advisory Role - Biocompatibles; Merck Serono; Novartis; Pfizer
Honoraria - Biocompatibles International; Merck Serono; Sanofi
Research Funding - Biocompatibles; Novartis